ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Expected of Fund Cancer Education Grants In Fiscal 1986; Final Fate to Be Decided This Week

March 7, 1986

Kulig Will Oversee Outcomes Research at NCCN

September 30, 2011

“Honor Roll” Of Top Investigators Who Won’t Be Funded Because Of Cuts

March 8, 1985

DCT Board to Study Modifications Of Existing Cooperative Group System

June 13, 1986

First Phase 0 Oncology Trial Demonstrates Effectiveness Of New Drug On Its Target

April 24, 2009

Oklahoma Cancer Center Recruits Four Professors.

June 15, 2001